SIO GENE THERAPIES
Sio Gene Therapies, formerly known as Axovant, is a clinical-stage company with a singular focus on pushing the boundaries of gene therapy to develop treatments for debilitating neurodegenerative diseases, including GM1 gangliosidosis, Tay-Sachs/Sandhoff disease, and Parkinson’s disease. Sio is leveraging its foundational scientific expertise built on decades of research, extensive collaborations with leading gene therapy institutes, and a flexible vector platform to liberate patients with debilitating diseases through the transformational power of gene therapies.
SIO GENE THERAPIES
Industry:
Biopharma Biotechnology Neuroscience Therapeutics
Founded:
2014-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.siogtx.com
Total Employee:
101+
Status:
Active
Contact:
833-296-8268
Email Addresses:
[email protected]
Total Funding:
129.7 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail IPv6 Amazon Route 53 Pound Sterling Typekit Microsoft New Relic
Similar Organizations
Alpha Omega
Defining Neuroscience Technology
Avalo Therapeutics
Avalo Therapeutics is a clinical-stage biopharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
Minerva Neuroscience
Minerva Neurosciences is a clinical-stage biopharmaceutical company
SAB Biotherapeutics
SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.
SELLAS Life Sciences
SELLAS Life Sciences is a late-stage biopharmaceutical company.
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company that develops treatments for diseases with high unmet need.
UroGen Pharma
UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing novel therapies.
Vyriad
Vyriad is a clinical stage biopharmaceutical company.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - Sio Gene Therapies
Official Site Inspections
http://www.siogtx.com Semrush global rank: 8.57 M Semrush visits lastest month: 286
- Host name: misenopa.tempurl.host
- IP address: 64.176.205.192
- Location: Andover United States
- Latitude: 42.6508
- Longitude: -71.1607
- Metro Code: 506
- Timezone: America/New_York
- Postal: 01810
More informations about "Sio Gene Therapies"
Sio Gene Therapies - Crunchbase Company Profile
Contact Email [email protected] Phone Number 833-296-8268 Sio Gene Therapies, formerly known as Axovant, is a clinical-stage company with a singular focus on pushing the boundaries of gene therapy to develop treatments for …See details»
Sio Gene Therapies Announces Prioritization of Lead Gene Therapy ...
Jan 31, 2022 Mr. Nassif added, “I’m honored to take the helm of Sio as we solidify the focus of the organization on rare genetic diseases and extend our cash runway into the second half of …See details»
Sio Gene Therapies - Wikipedia
Sio Gene Therapies, Inc. (formerly known as Axovant Gene Therapies) was a clinical-stage pharmaceutical company that developed gene therapies to treat neurological disorders. The company was headquartered in New York City and was incorporated in Basel, Switzerland. The company was founded by former hedge fund analyst and 2024 Republican Party presidential primary candidate See details»
Axovant Gene Therapies Announces Name Change to Sio Gene …
Nov 10, 2020 * Rebranding to Sio Gene Therapies to reflect an independent company with a scientific strategy focused on disease-modifying and curative genetic medicines * Company’s …See details»
Sio Gene Therapies Announces Reorganization of R&D Group
Oct 21, 2021 Two new executive positions created in connection with departure of R&D HeadNEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene …See details»
Sio Gene Therapies Announces Prioritization of Lead Gene Therapy ...
Jan 31, 2022 For more information, visit www.siogtx.com. Forward-Looking Statements. This press release contains forward-looking statements for the purposes of the safe harbor …See details»
Sio Gene Therapies Announces Reorganization of R&D Group
Oct 21, 2021 “Gavin has been instrumental in leading our R&D organization through a period of growth as we evolved our business model towards the development of CNS gene therapies,” …See details»
Corporate Presentation - siogtx.com
FORWARD-LOOKING STATEMENTS 2 This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform …See details»
Axovant Gene Therapies Announces Name Change to Sio Gene …
Nov 10, 2020 --Axovant Gene Therapies Ltd., a clinical-stage gene therapy company developing innovative gene therapies for neurodegenerative diseases, today announced it will change its …See details»
Sio Gene Therapies Inc. Announces Board Approval of Plan of
NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (Nasdaq:SIOX) today announced that its Board of Directors has determined, after...See details»
Sio Gene Therapies Announces Successful Manufacture of
Nov 11, 2021 [email protected]. Investors and Analysts. David W. Nassif Sio Gene Therapies Inc. Chief Financial Officer and General Counsel [email protected] ...See details»
Sio Gene Therapies Inc. Announces Board Approval of Plan of …
NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (Nasdaq:SIOX) today announced that its Board of Directors has determined, after extensive and careful …See details»
Sio Gene Therapies Appoints Gene Therapy Pioneer Guangping
Nov 19, 2020 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. (NASDAQ: SIOX), a clinical-stage company focused …See details»
Sio Gene Therapies Announces First Patient Dosed in Clinical Trial …
- First potentially disease-modifying gene therapy for GM2 gangliosidosis to enter clinical studies- Expect to continue patient identification, screening, and enrollment in Stage 1 of the study ...See details»
Sio Gene Therapies Announces Positive Interim Safety and
Oct 21, 2021 A replay will be archived on the Company’s website at www.siogtx.com after the conference call.. About AXO-AAV-GM1. AXO-AAV-GM1 delivers a functional copy of the …See details»
Sio Gene Therapies Announces Receipt of $11.6 Million from
Feb 4, 2021 Josephine Belluardo, Ph.D. LifeSci Communications (646) [email protected] [email protected] Investors and Analysts David Nassif Sio Gene …See details»
Gene Therapy Clinical Trial for Tay-Sachs and Sandhoff Diseases
[email protected]. Where can I find more information on GM2 gangliosidosis? • Global patient organizations such as the ones below have many helpful disease related resources. Version 1 …See details»
Sio Gene Therapies Announces Positive Six-Month Follow-Up Data …
Dec 15, 2020 Sio undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.Contacts:Media …See details»
Sio Gene Therapies Announces Corporate Updates and Fiscal First …
Aug 12, 2021 – Completed targeted enrollment of Type II patients in ongoing dose-escalation study of AXO-AAV-GM1 in GM1 gangliosidosis – On track to report 12-month topline safety, …See details»
Sio Gene Therapies Announces First Patient Dosed in
Feb 3, 2021 - First potentially disease-modifying gene therapy for GM2 gangliosidosis to enter clinical studies- Expect to continue patient identification, screening,...See details»